These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 23682923)

  • 21. Towards better ICU antibiotic dosing.
    Lipman J
    Crit Care Resusc; 2000 Dec; 2(4):282-9. PubMed ID: 16597315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Theoretical pharmacokinetic drug alterations in pediatric celiac disease.
    Tran TH; Smith C; Mangione RA
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1539-50. PubMed ID: 26155875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Considerations when administering medications enterally in the critically ill.
    MacLaren R
    Curr Opin Clin Nutr Metab Care; 2023 May; 26(3):302-306. PubMed ID: 36942898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
    Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
    J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Provision of enteral nutrition during vasopressor therapy for hemodynamic instability: an evidence-based review.
    Wells DL
    Nutr Clin Pract; 2012 Aug; 27(4):521-6. PubMed ID: 22689719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early enteral nutrition in critically ill patients.
    Rubinsky MD; Clark AP
    Dimens Crit Care Nurs; 2012; 31(5):267-74. PubMed ID: 22874539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients.
    Mahmoudi L; Mohammadpour AH; Ahmadi A; Niknam R; Mojtahedzadeh M
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):285-91. PubMed ID: 23426530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infectious diseases in the critically ill patients.
    Martin SJ; Yost RJ
    J Pharm Pract; 2011 Feb; 24(1):35-43. PubMed ID: 21507873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of meropenem in critically ill patients with severe infections.
    Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
    Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alterations of drug metabolism in critically ill animals.
    Hackett ES; Gustafson DL
    Vet Clin North Am Small Anim Pract; 2011 Jul; 41(4):805-15, vii. PubMed ID: 21757094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Posaconazole plasma concentrations in critically ill patients.
    Ray J; Campbell L; Rudham S; Nguyen Q; Marriott D
    Ther Drug Monit; 2011 Aug; 33(4):387-92. PubMed ID: 21654350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
    Lai Y; Varma M; Feng B; Stephens JC; Kimoto E; El-Kattan A; Ichikawa K; Kikkawa H; Ono C; Suzuki A; Suzuki M; Yamamoto Y; Tremaine L
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):723-43. PubMed ID: 22509796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic drug-drug interactions in the intensive care unit - single-centre experience and literature review.
    Łój P; Olender A; Ślęzak W; Krzych ŁJ
    Anaesthesiol Intensive Ther; 2017; 49(4):259-267. PubMed ID: 29027654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of liver and renal dysfunction on the pharmacokinetics of sedatives and analgesics in the critically ill patient.
    Yogaratnam D; Miller MA; Smith BS
    Crit Care Nurs Clin North Am; 2005 Sep; 17(3):245-50. PubMed ID: 16115532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Drug interactions in intensive care medicine].
    Peters H; Sakka SG
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2014 May; 49(5):326-34; quiz 335. PubMed ID: 24863334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delayed enteral feeding impairs intestinal carbohydrate absorption in critically ill patients.
    Nguyen NQ; Besanko LK; Burgstad C; Bellon M; Holloway RH; Chapman M; Horowitz M; Fraser RJ
    Crit Care Med; 2012 Jan; 40(1):50-4. PubMed ID: 21926614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switch from intravenous to enteral moxifloxacin in critically ill patients: a pilot study.
    de Smet J; Colpaert K; de Paepe P; van Bocxlaer J; Decruyenaere J; Boussery K
    Scand J Infect Dis; 2012 Nov; 44(11):874-8. PubMed ID: 22804100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Introduction to drug pharmacokinetics in the critically ill patient.
    Smith BS; Yogaratnam D; Levasseur-Franklin KE; Forni A; Fong J
    Chest; 2012 May; 141(5):1327-1336. PubMed ID: 22553267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of high physical activity on pharmacokinetic drug interactions.
    Lenz TL
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):257-66. PubMed ID: 21244343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does inhibition of P-glycoprotein lead to drug-drug interactions?
    Balayssac D; Authier N; Cayre A; Coudore F
    Toxicol Lett; 2005 Apr; 156(3):319-29. PubMed ID: 15763631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.